Navigation
banner
Together we Drive the Future

Neurodegenerative Diseases Research & Development

2017-06-292017-07-112017-06-16
EARLY BIRD DISCOUNT! Register by Jul 11, 2017 to receive 20% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


2017 Agenda
Day 1 - Monday, September 11th, 2017
7:30
Registration & Continental Breakfast
10:00
Morning Networking Break
Experimental Therapeutics & Approaches in Alzheimer’s Disease & Related Dimentia

10:45
Gabriela Chiosis
Gabriela Chiosis
Professor
MSKCC
About Speaker: ... Read Full Bio 
 
 
Gabriela Chiosis
Professor
MSKCC
 
About Speaker:
11:10
Robert Bell
Robert Bell
Senior Principal Scientist, Neurovascular Biology Lab Head
Pfizer
About Speaker: ... Read Full Bio 
 
 
Robert Bell
Senior Principal Scientist, Neurovascular Biology Lab Head
Pfizer
 
About Speaker:
11:35
Cheryl  Wellington
Cheryl Wellington
Clinical Professor, Djavad Mowafaghian Centre for Brain Health
University of British Columbia
About Speaker: ... Read Full Bio 
 
 
Cheryl Wellington
Clinical Professor, Djavad Mowafaghian Centre for Brain Health
University of British Columbia
 
About Speaker:
12:00
Sharon  Rosenzweig-Lipson
Sharon Rosenzweig-Lipson
Vice President of R&D
Agenebio
About Speaker: ... Read Full Bio 
 
 
Sharon Rosenzweig-Lipson
Vice President of R&D
Agenebio
 
About Speaker:
12:25
Sponsored Lunch Workshop on Preclinical Models
Advances in Parkinson’s Disease Research & Therapeutics

1:55
Targeting Glucocerebrosidase for Parkinson’s Disease
 
Gayathri Ramaswamy
Gayathri Ramaswamy
Lab Head, Internal Medicine Research Unit
Pfizer
About Speaker: Dr. Gayathri Ramaswamy is the head of Lipids and Lysosomes lab and Senior Principal Scientist in the Internal Medicine Research Unit at Pfizer Inc. Dr. Ramaswamy obtained her Ph.D. from St. Jude Children’s Research Hospital, University of Tennessee... Read Full Bio 
 
 
Gayathri Ramaswamy
Lab Head, Internal Medicine Research Unit
Pfizer
 
About Speaker:

Dr. Gayathri Ramaswamy is the head of Lipids and Lysosomes lab and Senior Principal Scientist in the Internal Medicine Research Unit at Pfizer Inc. Dr. Ramaswamy obtained her Ph.D. from St. Jude Children’s Research Hospital, University of Tennessee (Memphis) and did her post-doctoral training at Gladstone Institute of Neurological Diseases, University of California (San Francisco). She has more than 18 years of experience in lipid metabolism and is considered an expert in apolipoprotein E (apoE) and its role in Alzheimer’s disease. Dr. Ramaswamy has made seminal contributions to understanding the underlying mechanism(s) by which apoE4 contributes to AD. Additionally, she is an expert in small molecule phenotypic screen deconvolution, molecular biology and cell biology. She has also developed reagents for identifying bio-threat agents and for evaluating target gene expression. She has co-authored several peer-reviewed publications. Currently, Dr. Ramaswamy is leading drug discovery programs for treating Alzheimer’s disease and Parkinson’s disease respectively. Areas of research in her laboratory include understanding the underlying mechanisms that regulate apoE in the brain, mechanistic role of apoE4 in AD, and interrogating the role of lipids and lysosome dysfunction in neurodegenerative diseases.

 
Abstract: ...Read More 

Glucocerebrosidase 1 (GBA1) is a lysosomal hydrolase that breaks down the glycolipid, glucocerebroside into ceramide and glucose. Deficiency in GBA1 caused by mutations in the GBA1 gene leads to accumulation of the glycolipid substrate in lysosomes in Gaucher’s disease, a rare lysosomal storage disorder. More recently, mutations in GBA1 have been found to be associated with increased risk and reduced age of onset of Parkinson’s disease (PD). Furthermore, these mutations lead to a decrease in GBA1 enzyme activity and have been found to be associated with increased alpha-synuclein accumulation in brains from PD patients. Given the compelling genetic association and underlying pathophysiology, targeting GBA1 seems to be an attractive strategy for treating PD. This presentation will address the following:
1. What is the association of GBA1 to PD?
a. Present data on the genetic link.
b. Discuss mechanistic link to the disease.
2. What are the potential strategies for targeting GBA1 for treating PD?

 Read Less
2:20
Malu Tansey
Malu Tansey
Associate Professor, Physiology
Emory University
About Speaker: ... Read Full Bio 
 
 
Malu Tansey
Associate Professor, Physiology
Emory University
 
About Speaker:
2:45
Errol  De Souza
Errol De Souza
President & Chief Executive Officer
Neuropore Therapies
About Speaker: ... Read Full Bio 
 
 
Errol De Souza
President & Chief Executive Officer
Neuropore Therapies
 
About Speaker:
3:11
Katrina Paumier
Katrina Paumier
Assistant Professor of Neurology
Washington University School of Medicine
About Speaker: ... Read Full Bio 
 
 
Katrina Paumier
Assistant Professor of Neurology
Washington University School of Medicine
 
About Speaker:
3:35
Afternoon Networking Break
Round Table Session -Neuroinflammation, Neuroimaging, & Translational Biomarkers
5:35
Networking Reception & Poster Session
Day - 2 Tuesday, September 12th, 2017
7:15
Breakfast with Mentors from Academia & Industry
Next Frontier in Multiple Sclerosis to Limit or Reverse Neurodegeneration

8:30
Francisco Quintana
Francisco Quintana
Associate Professor of Neurology
Harvard Medical School
About Speaker: Francisco J. Quintana, PhD is an Associate Professor of Neurology at the Center for Neurologic Diseases, at Brigham and Women’s Hospital, Harvard Medical School, and an Associate Member at the Broad Institute of Harvard and MIT. Dr. Quintana, ... Read Full Bio 
 
 
Francisco Quintana
Associate Professor of Neurology
Harvard Medical School
 
About Speaker:

Francisco J. Quintana, PhD is an Associate Professor of Neurology at the Center for Neurologic Diseases, at Brigham and Women’s Hospital, Harvard Medical School, and an Associate Member at the Broad Institute of Harvard and MIT.

Dr. Quintana, a graduate of the University of Buenos Aires (1999, Argentina), obtained his PhD in immunology at the Weizmann Institute of Science (2004, Israel). He received postdoctoral training at the Weizmann Institute of Science and at Harvard Medical School. In 2009, Dr. Quintana joined the faculty of Harvard Medical School.

Dr. Quintana’s research investigates signaling pathways that control the immune response and neurodegeneration, with the ultimate goal of identifying novel therapeutic targets and biomarkers for immune-mediated disorders. Dr. Quintana has published over 140 peer reviewed articles and book chapters. In addition, Dr. Quintana’s research has resulted in multiple patents which have been the foundation of three companies: ImmunArray Ltd, Alma Bio Therapeutics and AnTolRx Inc.

Dr. Quintana is the recipient of the Lady Anne Chain Prize for Academic Excellence and Scientific Achievements, the Junior Investigator Award from the National Multiple Sclerosis Society, the Pathway to Independence Award of the National Institute of Allergy and Infectious Diseases, the Award for Outstanding Research Achievement form Nature Biotechnology and the Tecan Award for Innovation, the Harry Weaver Award from the National Multiple Sclerosis Society.

8:55
James Salzer
James Salzer
Professor, Department of Neuroscience and Physiology
NYU School of Medicine
About Speaker: ... Read Full Bio 
 
 
James Salzer
Professor, Department of Neuroscience and Physiology
NYU School of Medicine
 
About Speaker:
10:10
Morning Networking Break
Therapeutics for Rare & Orphan CNS Disorders

10:40
Michael Yeaman
Michael Yeaman
Professor of Medicine, David Geffen School of Medicine
UCLA
About Speaker: ... Read Full Bio 
 
 
Michael Yeaman
Professor of Medicine, David Geffen School of Medicine
UCLA
 
About Speaker:
11:05
Michelle Hastings
Michelle Hastings
Associate Professor of Cell Biology and Anatomy
Rosalind Franklin University/Chicago Medical School
About Speaker: ... Read Full Bio 
 
 
Michelle Hastings
Associate Professor of Cell Biology and Anatomy
Rosalind Franklin University/Chicago Medical School
 
About Speaker:
11:30
Thomas  Kukar
Thomas Kukar
Assistant Professor
Emory University School of Medicine
About Speaker: ... Read Full Bio 
 
 
Thomas Kukar
Assistant Professor
Emory University School of Medicine
 
About Speaker:
11:55
Arti  Gaur
Arti Gaur
Assistant Professor of Neurology
Dartmouth Geisel School of Medicine
About Speaker: ... Read Full Bio 
 
 
Arti Gaur
Assistant Professor of Neurology
Dartmouth Geisel School of Medicine
 
About Speaker:
12:20
Ready, Set, Grow – New Company Technology Pitch Competition & Lunch
Award Ceremony & Closing Keynote Session – Predictions for future

1:35
Rudolph Tanzi
Rudolph Tanzi
Vice-Chair Neurology Research
Massachusetts General Hospital, Harvard Medical School
About Speaker: Dr. Rudolph Tanzi is the Vice-Chair of Neurology and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital, and serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School. Dr. Tanzi re... Read Full Bio 
 
 
Rudolph Tanzi
Vice-Chair Neurology Research
Massachusetts General Hospital, Harvard Medical School
 
About Speaker:

Dr. Rudolph Tanzi is the Vice-Chair of Neurology and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital, and serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School.
Dr. Tanzi received his B.S. (microbiology) and B.A. (history) at the University of Rochester in 1980 and his Ph.D. (neurobiology) at Harvard Medical School in 1990. In his research achievements, Dr. Tanzi served on the team that was the first to find a disease gene ((Huntington’s disease) using human genetic markers, helping to launch the field of neurogenetics.
Dr. Tanzi co-discovered all three early-onset familial Alzheimer’s disease genes and identified several others as leader of the Alzheimer’s Genome Project supported by the Cure Alzheimer’s Fund, for which Dr. Tanzi also serves Chair of the Research Consortium. He also discovered the Wilson’s disease gene and several other neurological disease genes. He and his team used Alzheimer’s genes and human stem cells to create “Alzheimer’s-in-a-Dish”. This is a three-dimensional human stem cell-derived neural culture system that is the first to recapitulate both pathological hallmarks of Alzheimer’s disease: plaques and tangles. This model has made drug screening for Alzheimer’s disease considerably faster and more effective. Dr. Tanzi has developed several novel therapies for AD including gamma secretase modulators aimed at plaque pathology. Most recently, Dr. Tanzi and his team have discovered that beta-amyloid, the main component of senile plaques, may play a role in the innate immune system of the brain operating as an anti-microbial peptide, suggesting a possible role for infection in the etiology and pathogenesis of AD.
Dr. Tanzi has published over 500 research papers and has received the highest awards in his field, including the Metropolitan Life Foundation Award, Potamkin Prize, Ronald Reagan Award, Silver Innovator Award, and the Smithsonian American Ingenuity Award, the top national award for invention and innovation. He serves on dozens of editorial boards and scientific advisory boards and was named to TIME magazine’s list of TIME100 Most Influential People in the World (2015). He co-authored the popular trade books “Decoding Darkness”, New York Times bestseller, “Super Brain”, and international bestseller “Super Genes”.

Keynote Discussion Panel
3:05
Conference Concludes